CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies / 医学前沿
Frontiers of Medicine
; (4): 783-804, 2021.
Article
在 En
| WPRIM
| ID: wpr-922520
Responsible library:
WPRO
ABSTRACT
The current standard of care in hematological malignancies has brought considerable clinical benefits to patients. However, important bottlenecks still limit optimal achievements following a current medical practice. The genetic complexity of the diseases and the heterogeneity of tumor clones cause difficulty in ensuring long-term efficacy of conventional treatments for most hematological disorders. Consequently, new treatment strategies are necessary to improve clinical outcomes. Chimeric antigen receptor T-cell (CAR T) immunotherapy opens a new path for targeted therapy of hematological malignancies. In this review, through a representative case study, we summarize the current experience of CAR T-cell therapy, the management of common side effects, the causative mechanisms of therapy resistance, and new strategies to improve the efficacy of CAR T-cell therapy.
Key words